Search
for
Sort by
Research 91–120 of 230
- Real‐world experience and long‐term evaluation of tofacitinib in refractory alopecia areata: A prospective, open‐label, single‐center study in Asian Arab population
- LB1034 Meta-analysis of scalp transcriptome defines alopecia areata subtypes and molecular response to four (4) treatments with jak inhibiting properties
- JAK inhibitors in dermatology: The promise of a new drug class
- Emerging Topical and Systemic JAK Inhibitors in Dermatology
- Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib
- Pharmacologic inhibition of JAK-STAT signaling promotes hair growth
- A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results
- Targeting the Janus Kinase Family in Autoimmune Skin Diseases
- Evaluating the Therapeutic Potential of Ritlecitinib for the Treatment of Alopecia Areata
- The influence of interferon on healthy and diseased skin
- JAK inhibition in the treatment of alopecia areata – a promising new dawn?
- Developing a JAK Inhibitor for Targeted Local Delivery: Ruxolitinib Cream
- Comparative efficacy of oral Janus kinase inhibitors and biologics in adult alopecia areata: A systematic review and Bayesian network meta‐analysis
- Application of Baricitinib in Dermatology
- Under Development JAK Inhibitors for Dermatologic Diseases
- Off-Label Uses of Abrocitinib: Review of Emerging Therapeutic Applications beyond Atopic Dermatitis
- Alopecia Areata: Case report and review of pathophysiology and treatment with Jak inhibitors
- Case report: Psoriasiform eczema with immune-mediated comorbidities treated with upadacitinib
- Ivarmacitinib for the treatment of adults with severe alopecia areata: Results from a phase 3 trial
- Post-marketing safety signals of four JAK inhibitors for alopecia areata: an indication-restricted FAERS pharmacovigilance study
- Janus kinase inhibitors for alopecia areata: A narrative review
- Adverse events in patients treated with Jak‐inhibitors for alopecia areata: A systematic review
- Population exposure–response analysis of the effect of ritlecitinib on eyebrow assessment and eyelash assessment in patients with alopecia areata
- Novel Janus Kinase Inhibitors in the Treatment of Dermatologic Conditions
- JAK-Inhibitors Beyond the Label: Emerging Applications in Dermatology
- Ritlecitinib: Efficacy of a Novel Therapy for Severe Alopecia Areata in Patients Aged 12 Years and Older
- Hair follicle targeting via gelatin coated transferosomes loaded with tofacitinib citrate for enhanced treatment of alopecia areata: Clinical evaluation of alopecia areata patients
- 496 Understanding the mechanism of action of secukinumab using lesional hidradenitis suppurativa skin organ culture
- Comparative efficacy and safety of JAK inhibitors in the treatment of moderate-to-severe alopecia areata: a systematic review and network meta-analysis
- Mendelian randomization study highlights hypothyroidism as a causal determinant of alopecia areata